Ervina Bilic

Prof. Ervina Bilic

Head of the Department of Neurology Clinical Hospital Center Zagreb
+2
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
GCGeoffrey D.E. Cuvelier
Geoffrey D.E. Cuvelier
MSMichelle Schoettler
Michelle Schoettler
NBNataliya Buxbaum
Nataliya Buxbaum
IPIago Pinal-Fernandez
Iago Pinal-Fernandez
MSMarc Schmalzing
Marc Schmalzing
DWDaniel Wolff
Daniel Wolff
Alloreactive and autoimmune responses after allogeneic hematopoietic cell transplantation can occur in nonclassical chronic graft-versus-host disease (chronic GVHD) tissues and organ systems or manifest in atypical ways in classical organs commonly affected by chronic GVHD. The National Institutes of Health (NIH) consensus projects were developed to improve understanding and classification of the clinical features and diagnostic criteria for chronic GVHD. Although still speculative whether atypical manifestations are entirely due to chronic GVHD, these manifestations remain poorly captured by the current NIH consensus project criteria. Examples include chronic GVHD impacting the hematopoietic system as immune mediated cytopenias, endothelial dysfunction, or as atypical features in the musculoskeletal system, central and peripheral nervous system, kidneys, and serous membranes. These purported chronic GVHD features may contribute significantly to patient morbidity and mortality. Most of the atypical chronic GVHD features have received little study, particularly within multi-institutional and prospective studies, limiting our understanding of their frequency, pathogenesis, and relation to chronic GVHD. This NIH consensus project task force report provides an update on what is known and not known about the atypical manifestations of chronic GVHD while outlining a research framework for future studies to be undertaken within the next 3 to 7 years. We also provide provisional diagnostic criteria for each atypical manifestation, along with practical investigation strategies for clinicians managing patients with atypical chronic GVHD features.

6 June 2016 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
Ervina BilicErvina Bilic
Ervina Bilic
VDV Delimar
V Delimar
LDL Desnica
L Desnica
DPD Pulanic
D Pulanic
MBM Bakovic
M Bakovic
SPS Z Pavletic
S Z Pavletic
Increasing safety of allogeneic hematopoietic stem cell transplantation (allo-HSCT) has also increased the number of patients at risk for developing chronic GvHD (cGvHD). Peripheral nerve neurological manifestations and symptoms are being increasingly recognized in cGvHD, however, prospectively planned clinical studies have rarely been reported.

25 July 2022 in Cureus
Verified
Journal Article
Open access
AAAna Abicic
Ana Abicic
BSBarbara Sitaš
Barbara Sitaš
IAIvan Adamec
Ivan Adamec
Ervina BilicErvina Bilic
Ervina Bilic
Mario HabekMario Habek
Mario Habek
Coronavirus disease 2019 (COVID-19) vaccines have been reported as possible triggers of the production of antibodies pathogenic to the peripheral nerve and neuromuscular junction. We report on a patient who experienced vertical diplopia three weeks after the booster dose of the Pfizer-BioNTech vaccine (Comirnaty®). The diagnosis of myasthenia gravis (MG) was established based on highly positive antibodies to the nicotinic acetylcholine receptor (nAChR). Treatment with pyridostigmine and prednisone was started with gradually raising doses. On a follow-up exam two months after treatment initiation, clinical improvement was noted with an almost normal bulbomotor examination. The occurrence of diplopia following COVID-19 vaccination should raise suspicion of new-onset ocular MG and testing for anti-nAChR antibodies is advised.

26 October 2022 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
IAIvan Adamec
Ivan Adamec
GJGregor Brecl Jakob
Gregor Brecl Jakob
JDJelena S. Drulović
Jelena S. Drulović
JSJohann Sellner
Johann Sellner
Ervina BilicErvina Bilic
Ervina Bilic
Mario HabekMario Habek
Mario Habek

13 January 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
GSGrgur Salai
Grgur Salai
Ervina BilicErvina Bilic
Ervina Bilic
Dragan PrimoracDragan Primorac
Dragan Primorac
DLDarija Mahovic Lakušić
Darija Mahovic Lakušić
HBHrvoje Bilić
Hrvoje Bilić
LGLovorka Grgurevic
Lovorka Grgurevic
The BNT162b2 (Pfizer BioNTech) mRNA vaccine is an effective vaccine against COVID-19 infection. Here, we report an adverse event following immunization (AEFI) in a 48-year-old female patient who presented with fasciculations, migraine auras without headaches and in an increased discomfort of previously present palpitations, as well as excitation and insomnia. Her fasciculations were intermittently present until the time this paper was written, starting from the 6th day post-vaccination; they changed localization and frequency, but most commonly they were generalized, affecting almost all muscle groups. The patient also suffered from two incidents of migraine auras with visual kaleidoscope-like phenomena without headaches a few months after the vaccination. These symptoms were considered to be AEFI and no causal relation with the vaccine could be proven.